Ming-Wei Lin

Ming-Wei Lin

Auto-generated profile, based on publicly available information

Ming-Wei Lin

Institute of Public Health, National Yang Ming Chiao Tung University, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2023 in European Journal of Oncology Nursing
Verified
Journal Article
Closed access
YWYa-Jung Wang
Ya-Jung Wang
TJTsai Jung-Jung
Tsai Jung-Jung
LMLin Ming-Wei
Lin Ming-Wei
LTLing-Ming Tseng
Ling-Ming Tseng
CWChihJung Wu
ChihJung Wu

19 December 2023 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
ILI-Tien Lee
I-Tien Lee
YWYa-Jung Wang
Ya-Jung Wang
MLMing-Wei Lin
Ming-Wei Lin
TCTzeon-Jye Chiou
Tzeon-Jye Chiou
CWChihJung Wu
ChihJung Wu

6 June 2026 in Genetics in Medicine Open
Verified
Journal Article
Open access
KCKuang-Huan Cheng
Kuang-Huan Cheng
RKRalph Kirby
Ralph Kirby
MLMing-Wei Lin
Ming-Wei Lin
Chen-Chi WuChen-Chi Wu
Chen-Chi Wu
CHChih-Cheng Hsu
Chih-Cheng Hsu
STShih-Feng Tsai
Shih-Feng Tsai

11 August 2026 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
KCKuang-Huan Cheng
Kuang-Huan Cheng
YCYi-Rong Chen
Yi-Rong Chen
RCRen-Hua Chung
Ren-Hua Chung
MLMing-Wei Lin
Ming-Wei Lin
HWHui-Ying Weng
Hui-Ying Weng
STShih-Feng Tsai
Shih-Feng Tsai
Background: To enhance the efficiency of identifying rare variants within the Taiwanese population and to support genome-wide association studies (GWAS) and imputation studies for genetic risk prediction in the Han population, we have developed the National Health Research Institutes (NHRI) reference panel (NHRI-RP-1). Methods: NHRI-RP-1 is based on 2,561 whole genome sequences taken from the in-house NHRI datasets. Our objective was to optimize conditions of sample sizes (0.5K, 1K, 1.5K, 2K, 2.5K), minor allele frequency (MAF) thresholds (MAF ≥ 0.05, 0.01, 0.001, 2 × 10 –4 ), and imputation quality (r 2 ≥ 0, 0.3, 0.5) to build an aggregated genome reference panel for genetic medicine by comparing with worldwide references. Clinical applications and GWAS were then evaluated to demonstrate the capability of the reference panel. Results: Among different combinations of relevant parameters, the NHRI-RP-1 (with a 2,500-sample size, MAF ≥ 2 × 10 –4 , r 2 ≥ 0) demonstrated a superior F1 score on local match, genotype concordance and r-squared, as compared to those using worldwide reference genomes, particularly for rare MAFs. Furthermore, NHRI-RP-1 achieved over 95% accuracy for nine pathogenic variants present in the Taiwan Biobank and 93.49% and 92.9% accuracy for imputing two DRD1 variants. Conclusions: The use of different reference panels can influence the outcomes of GWAS. Our case studies demonstrate the utility of the NHRI-RP-1 for genetic medicine. Incorporating a population-specific panel such as NHRI-RP-1 can facilitate the development of prediction models using polygenic risk scores for diseases that are common in the Han population.

29 May 2026 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
HWHui-Ying Weng
Hui-Ying Weng
DLDing-Dar Lee
Ding-Dar Lee
YLYung-Feng Lin
Yung-Feng Lin
SLSheng-Hung Lee
Sheng-Hung Lee
YCYun-Ting Chang
Yun-Ting Chang
STShih-Feng Tsai
Shih-Feng Tsai
Primary Cutaneous Amyloidosis (PCA) is a skin-limited disorder more common in Southeast Asian. Previous studies have identified mutations located in a fibronectin type III-like repeat domain of OSMR gene, including p.G513D (c.1538G > A). To investigate the genetic background of PCA, we recruited a consecutive series of 91 unrelated PCA patients, and subjected to whole-exome sequencing (WES) for genomic analysis. We also analyzed population genomic data from Taiwan, Japan, Singapore, Vietnam, Brazil, and the USA to evaluate the distribution of OSMR variants across different countries and ethnicities. A genetic screening program was conducted on 37,770 individuals at a hospital using the Taiwan Precision Medicine Initiative array (TPMI). The OSMR variant, c.1538G > A p.G513D, was identified in 24.18% (22/91) of patients with PCA, compared to only 2.61% (39/1,495) in the control group from Taiwan Biobank (OR = 11.90; 95% CI: 6.69-21.17; p < 0.0001). Its proportion was higher among East Asians, particularly in Taiwanese, Vietnamese, and Chinese Singaporeans, and nearly absent in European or Japanese populations. A hospital-based genetic screening revealed that 2.5% (944/37,770) of individuals carried the OSMR p.G513D variant. Notably, 57.14% (4/7) of homozygous individuals were diagnosed with PCA, compared to 1.39% (13/937) of heterozygous individuals (OR = 94.77; 95% CI: 19.24-466.70; p < 0.0001). These findings establish OSMR p.G513D as a population-specific risk allele for PCA and highlight the need for ancestry-aware genetic screening in Southeast Asians.